Greenwich LifeSciences (GLSI) Cash from Financing Activities (2020 - 2026)

Greenwich LifeSciences (GLSI) has 5 years of Cash from Financing Activities data on file, last reported at $5.5 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 4452.04% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.0 million (up 174.64% YoY) and the FY2025 annual result came in at $12.0 million, up 174.64% from the prior year.
• Cash from Financing Activities climbed to $5.5 million in Q4 2025, from $3.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $5.5 million in Q4 2025 to a low of -$5.5 million in Q1 2022.
• A 4-year average of $972318.2 and a median of $872010.0 in 2021 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 342.59% — and 2025, when it jumped 4452.04%.
• Tracing GLSI's Cash from Financing Activities over 4 years: stood at $562596.0 in 2021, then tumbled by 459.5% to -$2.0 million in 2022, then jumped by 106.02% to $121829.0 in 2024, then jumped by 4452.04% to $5.5 million in 2025.
• The last three Cash from Financing Activities figures came in at $5.5 million (Q4 2025), $3.4 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.